Page 138 - 《中国药房》2023年4期
P. 138
[10] YADAV D,DEWANGAN H K. Pegylation:an important cal pharmacokinetics,pharmacodynamics,safety and effi‐
approach for novel drug delivery system[J]. J Biomater cacy of liposomal amphotericin B[J]. Clin Infect Dis,
Sci Polym Ed,2021,32(2):266-280. 2019,68(Suppl 4):S260-S274.
[11] RIVANKAR S. An overview of doxorubicin formulations [25] 胡海锦 . 两性霉素 B 制剂的发展及临床应用[J]. 中国合
in cancer therapy[J]. J Cancer Res Ther,2014,10(4): 理用药探索,2020,17(7):5-9.
853-858. [26] BASSETTI M,VENA A,RUSSO A,et al. Inhaled liposo‐
[12] 张曼玉,楼晨曦,曹傲能. 主动靶向载药脂质体在肿瘤治 mal antimicrobial delivery in lung infections[J]. Drugs,
疗中的研究进展[J]. 生物医学工程学杂志,2022,39(3): 2020,80(13):1309-1318.
633-638. [27] 鲁珊珊,魏晓慧. 抗生素脂质体的研究[J]. 中国抗生素杂
[13] RODALLEC A,BRUNEL J M,GIACOMETTI S,et al. 志,2018,43(8):979-989.
Docetaxel-trastuzumab stealth immunoliposome:develop‐ [28] CLANCY J P,DUPONT L,KONSTAN M W,et al. Phase
ment and in vitro proof of concept studies in breast cancer Ⅱ studies of nebulised Arikace in CF patients with Pseu‐
[J]. Int J Nanomedicine,2018,13:3451-3465. domonas aeruginosa infection[J]. Thorax,2013,68(9):
[14] MOGHIMIPOUR E,REZAEI M,RAMEZANI Z,et al. 818-825.
Folic acid-modified liposomal drug delivery strategy for [29] GRIFFITH D E,EAGLE G,THOMSON R,et al. Amika‐
tumor targeting of 5-fluorouracil[J]. Eur J Pharm Sci, cin liposome inhalation suspension for treatment-
2018,114:166-174. refractory lung disease caused by mycobacterium avium
[15] 王利媛,林华庆,陈靖文,等. 介导基因传递的新型阳离 complex(CONVERT):a prospective,open-label,rando-
子脂质体的研究[J]. 中国药房,2018,29(15):2152-2156. mized study[J]. Am J Respir Crit Care Med,2018,198
[16] 赵娜 . ApoE 修饰阳离子脂质体的制备及其功能的初步 (12):1559-1569.
研究[D]. 太原:山西医科大学,2016. [30] 吴正锋,彭钰君,柏银兰 . 疫苗佐剂的研究进展[J/OL].
[17] EFTEKHARI R B,MAGHSOUDNIA N,SAMIMI S,et 微生物学免疫学进展,2022:1-6[2023-01-13]. https://
al. Co-delivery nanosystems for cancer treatment:a review kns.cnki.net/kcms/detail/62.1120.r.20220811.1730.004.html.
[J]. Pharm Nanotechnol,2019,7(2):90-112. [31] WANG N,CHEN M N,WANG T. Liposomes used as a
[18] WANG J,GONG J B,WEI Z P. Strategies for liposome vaccine adjuvant-delivery system:from basics to clinical
drug delivery systems to improve tumor treatment efficacy immunization[J]. J Control Release,2019,303:130-150.
[J]. AAPS PharmSciTech,2022,23(1):27. [32] 国家药品监督管理局. 重组带状疱疹疫苗获批上市[EB/
[19] YAN W,LEUNG S S,TO K K. Updates on the use of li‐ OL].(2019-05-22)[2022-03-19]. https://www. nmpa. gov.
posomes for active tumor targeting in cancer therapy[J]. cn/directory/web/nmpa////zhuanti/ypqxgg/gggzjzh/201905-
Nanomedicine(Lond),2020,15(3):303-318. 22150701437.html.
[20] HUANG D,SUN L N,HUANG L,et al. Nanodrug deli- [33] SMALLEY RUMFIELD C,PELLOM S T,MORILLON
very systems modulate tumor vessels to increase the en‐ II Y M,et al. Immunomodulation to enhance the efficacy
hanced permeability and retention effect[J]. J Pers Med, of an HPV therapeutic vaccine[J]. J Immunother Cancer,
2021,11(2):124. 2020,8(1):e000612.
[21] LI C L,ZHAO X,DENG C X,et al. Pegylated liposomal [34] 李平,童智慧,于乐成 . 2019 冠状病毒病疫苗研究与应
mitoxantrone is more therapeutically active than mitoxan‐ 用进展[J/OL]. 解放军医学杂志,2022:1-11[2023-01-13].
trone in L1210 ascitic tumor and exhibits dose-dependent https://kns. cnki. net/kcms/detail/11.1056. R. 20220928.1947.
activity saturation effect[J]. Int J Pharm,2014,460(1/2): 004.html.
165-172. [35] 林茂铨,李东,褚丽新,等 . mRNA 疫苗技术概述及新型
[22] WANG W X,SHAO A N,ZHANG N,et al. Cationic 冠状病毒肺炎mRNA疫苗的研究进展[J]. 中国现代应用
polymethacrylate-modified liposomes significantly en‐ 药学,2022,39(7):996-1004.
hanced doxorubicin delivery and antitumor activity[J]. Sci [36] 王卡拉.国产新冠mRNA疫苗研发进展如何?两款已在
Rep,2017,7:43036. 海外获紧急使用授权[N/OL].(2022-12-13)[2023-01-13].
[23] MAYER L D,TARDI P,LOUIE A C. CPX-351:a na‐ https://baijiahao.baidu.com/s?id=1752102351445612351&
noscale liposomal co-formulation of daunorubicin and cy‐ wfr=spider&for=pc.
tarabine with unique biodistribution and tumor cell uptake (收稿日期:2022-04-14 修回日期:2023-01-15)
properties[J]. Int J Nanomedicine,2019,14:3819-3830. (编辑:邹丽娟)
[24] GROLL A H,RIJNDERS B J A,WALSH T J,et al. Clini‐
· 512 · China Pharmacy 2023 Vol. 34 No. 4 中国药房 2023年第34卷第4期